Q2 2024 Bactiguard Holding AB Earnings Call Transcript
Key Points
- Total revenues for Q2 2024 increased by almost 19% compared to the same period last year.
- Positive EBITDA for Q2 2024, indicating a move towards profitability.
- Expansion of Bactiguard coated products to new markets, including Japan.
- Strengthened R&D team with the appointment of Nathaniel Bachrach as Interim Head of R&D.
- Wound Management portfolio continues to deliver profitable growth, with Q2 revenues of approximately SEK15 million.
- EBITDA for the first half of 2024 was still negative at SEK0.3 million.
- Revenues from the BIP portfolio decreased by SEK3.3 million for Q2.
- The transition to new markets with BD is ongoing, with no immediate significant revenue impact expected for 2024.
- Operating expenses remain high, although there has been a decrease.
- The company is still in the process of completing transitional activities from its 2023 transformation.
Thank you, operator, and welcome to the presentation of Bactiguard Q2 2024 reports. I will go through the presentation together with our CFO, Patrick Bach, and open up for questions towards the end. Thank you all for dialing in today.
I have just completed my third month as CEO of Bactiguard. And my reflection from this time is that we have a lot of the building blocks in place to execute on our new strategy. We have been through a transformation. However, the team in place is very experienced and highly motivated to make the world a healthier place. While we still have transitional activities from the transformation to complete throughout the remainder of 2024, we are one team collaborating closely together with a solution oriented approach and a performance mindset.
Now turning to the developments of the second quarter Let me start with the figures on an overall level. Our total revenues for Q2 amounted to SEK60.9 million, an increase of almost 19% compared to the same period last year and for the first half to SEK119.7
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |